article Open AccessTop 1% cited
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study
Lara D. Veeken · 2009 · Vol. 49(1) · pp. 128–140
David Isenberg✉(University College London)Gerald B. Appel(Columbia University)Gabriel Contreras(University of Miami)Mary Anne Dooley(University of North Carolina at Charlotte)Ellen M. Ginzler(State University of New York)David Jayne(Addenbrooke's Hospital)Jorge Sánchez‐GuerreroDavid Wofsy(University of California, San Francisco)Xueqing Yu(The First Affiliated Hospital, Sun Yat-sen University)Neil Solomons
Abstract
MMF and IVC have similar efficacy overall to short-term induction therapy for LN. However, race, ethnicity and geographical region may affect treatment response; more Black and Hispanic patients responded to MMF than IVC. As these factors are inter-related, it is difficult to draw firm conclusions about their importance.
Systemic Lupus Erythematosus ResearchRenal Diseases and GlomerulopathiesInflammatory Bowel DiseaseMedicineLupus nephritisInternal medicinePrednisoneClinical endpointRenal functionAdverse effectGastroenterologySystemic lupus erythematosusRandomized controlled trial
MeSH terms
AdolescentAdultAgedChildCyclophosphamideDrug Administration ScheduleDrug Therapy, CombinationHumansImmunosuppressive AgentsLupus NephritisMiddle AgedMycophenolic AcidOpportunistic InfectionsPrednisoneProspective Studies
Funding
- Amgen
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Vifor Pharma
- Genentech
Citations
352
FWCI
16.05
field-weighted impact
References
41
Percentile
100%
vs. same field & year
Citations per year
Cited by
The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults
Lara D. Veeken · 2017 · 351 citations
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
Annals of the Rheumatic Diseases · 2012 · 1,018 citations
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
Arthritis & Rheumatism · 2012 · 1,404 citations
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Annals of the Rheumatic Diseases · 2023 · 803 citations
2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis
Annals of the Rheumatic Diseases · 2020 · 788 citations
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Kidney International · 2021 · 2,277 citations
References
Derivation of the sledai. A disease activity index for lupus patients
Arthritis & Rheumatism · 1992 · 4,551 citations
Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus
Arthritis & Rheumatism · 1997 · 11,386 citations
Immunosuppressive therapy in lupus nephritis: The Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamide
Arthritis & Rheumatism · 2002 · 1,058 citations
The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited
Journal of the American Society of Nephrology · 2004 · 1,987 citations
Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Journal of the American Society of Nephrology · 2009 · 1,093 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.